227 related articles for article (PubMed ID: 11249689)
1. Papillomavirus virus-like particles as anticancer vaccines.
Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
[TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
[TBL] [Abstract][Full Text] [Related]
6. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
Xu YF; Zhang YQ; Xu XM; Song GX
Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
[TBL] [Abstract][Full Text] [Related]
7. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
9. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
10. Update on human papillomavirus vaccines for cervical cancer.
Steller MA
Curr Opin Investig Drugs; 2002 Jan; 3(1):37-47. PubMed ID: 12054070
[TBL] [Abstract][Full Text] [Related]
11. Papillomavirus-like particle vaccines for cervical cancer.
Schiller JT
Mol Med Today; 1999 May; 5(5):209-15. PubMed ID: 10322313
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
[TBL] [Abstract][Full Text] [Related]
13. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
14. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
15. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
16. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
17. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
[TBL] [Abstract][Full Text] [Related]
19. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
20. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
